Norbinal
Pre-clinical- Indications
- ADHD, Major Depressive Disorder, Fragile X syndrome
Company intelligence / Profile preview
Avekshan
Alachua, FL, United Statesavekshan.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Avekshan develops next-generation treatments for ADHD and other neuropsychiatric conditions. Its lead program, AVK001—a fixed-dose combination of methylphenidate and naltrexone—aims to reduce stimulant abuse potential while maintaining efficacy. The company also develops Norbinal as a non-narcotic alternative. Clinical results are not yet published; programs are advancing toward clinical trials via expedited regulatory pathways.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules (e.g., methylphenidate, naltrexone)Fixed Dose CombinationsNon-narcotic therapeutics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Avekshan.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avekshan.